Claim 5; SEQ ID No 84; 424pp; English.

1 15:53:01 2004

us-09-771-161a-93.oli20p2n.rng

Manny Mary Mary Sylvenson

New human kinases and phosymatases and polynucleotides, useful for diagnosing, treating or reventing autoimmune or inflammatory disorders (e.g. AIDS, allergy or enemia), multiple sclerosis, osteoarthritis, cancer or hepatitis.

ABX75870 standard; cDNA; 1620 BP.

ABX75870;

30-APR-2003 (first entry)

```
US-09-771-161A-93 (1-232) x AAZ09246 (1-1931)
                                                                                                                                                                                                                                                           Query Match:
DB:
                                                                                                                                                                                                                                                                                                 Percent Similarity:
Best Local Similarity:
                                                                                                                                                                                                                                                                                                                                                                 Pred. No.:
                                                                                                                                                                                                                                                                                                                                                                                     Alignment Scores:
                                                                                                                                                                  8
  δ
                                            Вþ
                                                                                  δ
                                                                                                                            문
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             death, abnormal activity of the Fas/APO-1 receptor complex, abnormal death, abnormal activity of the five receptor complex, or abnormal activity of a caspase. activity of the five receptor complex, or abnormal activity of a caspase. Diseases that may be treated include cancer (particularly follicular lymphoma, carcinomas associated with mutations in p53 and hormone-dependent tumours), autoimmune disorders (e.g. systemic lupus erythematosis, immune-mediated glomerulonephritis), viral infections, erythematosis, immune-mediated glomerulonephritis), viral infections, hlzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular dystrophy, cereballar degeneration,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             WPI; 1999-494269/41.
P-PSDB; AAY31140.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        06-FEB-1998;
17-JUN-1998;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 12-AUG-1999
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               This invention describes the isolation of novel human caspase recruitment domain, CRAD-3 and CRAD-4 polymucleotides and proteins and a partial murine CARD-41 protein and genes. The genes and proteins of the invention are involved in the regulation of caspase activation. The caspase are involved in the regulation of caspase activation. The caspase are involved in the caspase activation of the invention are involved in the regulation of caspase activation.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Novel CARD-3 and CARD-4 genes and polypeptides used or treating regulation of cellular proliferation and differentiation and cell
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Bertin
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    08-DEC-1998;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    05-FEB-1999;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         W09940102-A1
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   antibodies can be used in screening assays, detection assays, predictive medicine and therapeutic and prophylactic methods of treatment. The methods may be used to diagnose and treat patients which are suffering
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           survival.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Example 2; Fig 1; 181pp; English
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (MILL-) MILLENNIUM PHARM INC
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   survival. The CARD proteins may also be used to for screen drugs or compounds which modulate their activity. The CARD-4 gene can express a long transcript that encodes CARD-4L, a short transcript that encodes CARD-4S or two CARD-4 splice variants, CARD-4Y and CARD-4Z. This sequent encodes the human CARD-3 protein described in the method of the invention
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              retinitis pigmentosa, spinal muscular dystrophy, cerebellar degeneration, anaemia, myelodysplastic syndrome, mycardial infarction, and stroke anaemia, myelodysplastic syndrome, mycardial infarction, and so can be used CARD-3 protein interacts with other cellular proteins, and so can be used for regulation of cellular proliferation and differentiation and cell for regulation of cellular proliferation and differentiation and cell
                                                                                                                                                                                                                                                                                                                                                                                                                                Sequence 1931
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ods may be used to diagnose and treat patients which are suffering a disorder associated with abnormal level or rate of apoptotic ce
                                                                                                                                 1153
                                              1213
                                        46 AsnSerGlySerProGluThrSerArgSerLeuProAlaProGlnAspAsnAspPheLeu 65
                                                                                                                                                                         σ
                                                                                                                              TTACAGAGTGTTTCAAGTGCCATTCACCTATGTGACAAGAAGAAAATGGAATTATCTCTG 1212
                                                                                                                                                     LeuGlnSerValSerSerAlaIleHisLeuCysAspLysLysLysMetGluLeuSerLeu
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  98US-00019942.
98US-00099041.
98US-00207359.
                                                                                                                                                                                                                                                                                                                                                                                                                                  BP; 613 A; 429
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         99WO-US002544
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 /*tag= a
/product= "CARD-3"
                                                                                                                                                                                                                                                             6.9e-119
128.00
99.12%
99.12%
55.17%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                            protein described in the method of the invention
                                                                                                                                                                                                                                                                                                                                                                                                                                  c;
                                                                                                                                                                                                                                                                                                                                                                                                                                    416
                                                                                                                                                                                                                                                                                                                                                Length:
Matches:
                                                                                                                                                                                                                                                                                    Mismatches:
Indels:
                                                                                                                                                                                                                                                                                                                              Conservative:
                                                                                                                                                                                                                                                                                                                                                                                                                                      <u>و</u>
                                                                                                                                                                                                                                                                                                                                                                                                                                      473
                                                                                                                                                                                                                                                                                                                                                                                                                                      <del>⊷</del>
                                                                                                                                                                                                                                                                                                                                                                                                                                      0 U; 0 Other;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       This sequence
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            cell
                                                   1272
```

お な な な な め め る

	,								
225 nLeuIeuGlnAsnLysSerMet 232 	205 sGlnMetGlyLeuGlnProTyrProGluIleLeuValValSerArgSerProSerLeuAs 225 	185 rThrAsplleGlnGlyGluGluPheAlaLysValIleValGlnLysLeuLysAspAsnLy 205 	165 pTyrGluLeuValSerThrLysProThrArgThrSerLysValArgGlnLeuLeuAspTh 185 	145 UAJaCysLeuAsnGlnSerLeuAspAlaLeuLeuSerArgAspLeuIleMetLysGluAs 165	125 oGlyIleAlaGlnGlnTrpIleGlnSerLysArgGluAspIleValAsnGlnMetThrGl 145	105 oCysGerSerAlaIleIleAsnProLeuSerThrAlaGlyAsnSerGluArgLeuGlnPr 125 	86 TrpAspSerThrIleSerGlySerGlnArgAlaAlaPheCysAspHisLysThrThr-Pr 105 	66 SerArgLyshlaGlnAspCysTyrPheMetLysLeuHisHisCysProGlyAsnHisSer 85	

8 8

유

AAX02558 standard; cDNA; 2098 BP.

AAX02558;

07-MAY-1999 (first entry)

Human B1 cDNA.

B1 protein; intracellular mediator; modulator; inflammation; cell\_death; cell\_survival\_pathway; intracellular\_signalling; AIDS; cancer; human; ss:

W09855507-A2

Sequence 1931 BP; 613 A; 429 C; 416 G; 473 T; 0 U; 0 Other;

992	933 AACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACCATCTTTAA 992	12
932 1750	873 CTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAAATTGAAAGATAACA	유 왕
	813 ACTATGAACTTGTTAGTACCAAGCCTACAAGACCTCAAAAGTCAGACAATTACTAGACA	정
812 1630	753 AAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCATGAAAGAGG	음 경
752 1570		유정
692 1510		各정
632 1450		유
572 1390	513 TATCTAGAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGGAAATCACA	용 성
512 1330	453 AAAATAGTGGTTCTCCTGAAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAATGATTTTT	A 55
452 1270		용 성
392 1210		B 53
0;	Query Match 40.9%; Score 682; DB 2; Length 1931; Best Local Similarity 99.9%; Pred. No. 0; Matches 732; Conservative 0; Mismatches 1; Indels 0; Gaps	<b>3 B</b> O

Db	δ	Дb	Ş	ρb
Db 1871 AAGGATATTTATA 1883	QY 1053 AAGGATATTTATA 1065	Db 1811 ATTTACTTCAAAATAA		
83	65	1811 ATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTGTTTCATAA 1870	993 ATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTGTTTTCATAA 1052	1751 AACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACCAICTTTAA 1810
		870	052	810

William & Months of the state o

AAZ09246 ID AAZC AAZ09246 standard; cDNA; 1931 BP

Human CARD-3 cDNA.

(first entry)

caspase activation; detection; screening; therapy; diagnosis; disease; apoptotic cell death; Fas/APO-1 receptor complex; TNF receptor complex; cancer; follicular lymphoma; carcinoma; p53 mutation; viral infection; hormone-dependent tumour; autoimmune disorder; Alzheimer's disease; systemic lupus erythematosis; immune-mediated glomerulonephritis; stroke; Parkinson's disease; amyotrophic lateral sclerosis; retinitis pigmentosa; spinal muscular dystrophy; cerebellar degeneration; anaemia; drug; myelodysplastic syndrome; myocardial infarction; cell proliferation; cell differentiation; cell survival; CARD-41; CARD-45; CARD-47; CARD-47; CARD-3; caspase recruitment domain; CARD-4;

regulation; detection;

Homo sapiens.

Location/Qualifiers 214. .1836 /\*tag= a

FXEX CONTROL OF THE C 06-FEB-1998; 17-JUN-1998; 08-DEC-1998; Novel CARD-3 and CARD-4 genes and polypeptides used or treating regulation of cellular proliferation and differentiation and cell Example 2; Fig 1; 181pp; English 05-FEB-1999; WO9940102-A1 (MILL-) MILLENNIUM PHARM INC 1999-494269/41. 98US-00099041. 98US-00207359. 98US-00019942. 99WO-US002544 /product= "CARD-3"

retinitis pigmentosa, spinal muscular dystrophy, cerebellar degeneration, anaemia, myelodysplastic syndrome, myocardial infarction, and stroke.

CARD-3 protein interacts with other cellular proteins, and so can be used for regulation of cellular proliferation and differentiation and cell survival. The CARD proteins may also be used to for screen drugs or compounds which modulate their activity. The CARD-4 gene can express a long transcript that encodes CARD-41, a short transcript that encodes CARD-45 or two CARD-4 splice variants, CARD-47 and CARD-42. This sequence encodes the human CARD-3 protein described in the method of the invention recruitment domain (CARD) polynucleotides, polypeptides, homologues and antibodies can be used in screening assays, detection assays, predictive medicine and therapeutic and prophylactic methods of treatment. The methods may be used to diagnose and treat patients which are suffering from a disorder associated with abnormal level or rate of apoptotic cell death, abnormal activity of the TNF receptor complex, or abnormal activity of a caspase. Diseases that may be treated include cancer (particularly follicular lymphoma, carcinomas associated with mutations in p53 and hormonedependent tumours), autoimmune disorders (e.g. systemic lupus erythematosis, immune-mediated glomerulonephritis), viral infections, alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retribitis nigmantogs aprilar discretas for the property of t murine CARD-41 protein and genes. The genes and proteins of the invention are involved in the regulation of caspase activation. The caspase recruitment domain (CARD) polynucleotides, polypeptides, homologues and This invention describes the isolation of novel human caspase recruitment domain, CARD-3 and CARD-4 polynucleotides and proteins and a partial

Sequence 1931 BP; 613 A; 429 C; 416 G; 473 T; 0 U; 0 Other;

8 밁 S 밁 Matches Local 143 12 74.5%; Similarity 99.7%; GICAGCICIGGITCGGAGAAGCAGCGGCTGGCGTGGGCCATCCGGGGAATGGGCGCCCTC GTGACCTAGTGTTGCGGGGCAAAAAAGGGTCTTGCCGGCCTCGCTGCAGGGGGCGTATC GTCAGCTCTGGTTCGGAGAAGCAGCGGCTGGCCTTGGCCTTGGCCATCCGGGGAATGGGCCCCTC Conservative 0; Score 1864; DB 4; Pred. No. 5.3e-06; Mismatches Length 1931; Indels 0 191 202 142 131

ACCGGCCTGAGCGCCCGGGACCATGAACGGGGAGGCCATCTGCAGCGCCCCTGCCCACCAT

g 5 밁

S g Ş 멂 5 B δ

S В

Ś В 5 뮹

밁 δ 뮍

В 8 밁 8 밁 S

8 밁 Ś 밁 Ś

名、品

문 Ś 밁

S

G

52 52 112 112 112 113 113 113 115 115 115 115 115 115 115	263 TCCCTACCACAACTCGCCGACCTGCGCTACCTGAGCCGGGGGGCGCTCTGGGACTGTTC 322 [
	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
RESULT	